Table 7.
Effect on Final Weight Loss, All Patients - Adjusted Analyses.
| Young adults (19–25 years old) | Adolescents (13–18 years old) | Children (5–12 years old) | ||||
|---|---|---|---|---|---|---|
| ‡N = 665 medication instances | ‡N = 299 medication instances | ‡N = 41 medication instances | ||||
| %TBW (95% CI) | P-value | ΔBMIz (95% CI) | P-value | ΔBMIz (95% CI) | P-value | |
| Medication* | ||||||
| Metformin | −0.66 (−1.5–0.2) | >0.1 | 0.00 (0.0–0.0) | >0.1 | −0.02 (−0.1–0.0) | >0.1 |
| Topiramate | 1.47 (0.3–2.6) | 0.01 | −0.07 (−0.1–0.0) | 0.02 | −0.03 (−0.1–0.1) | >0.1 |
| Bupropion | −1.33 (−2.7–0.0) | 0.05 | 0.03 (−0.1–0.1) | >0.1 | 0.15 (−0.1–0.4) | >0.1 |
| Phentermine | 1.54 (0.0–3.0) | 0.05 | 0.12 (0.0–0.2) | 0.003 | — | — |
| Zonisamide | −4.27 (−10.2–1.6) | >0.1 | −0.07 (−0.2–0.0) | >0.1 | — | — |
| Naltrexone | 2.48 (−0.3–5.3) | 0.08 | — | — | — | — |
| Orlistat | −1.35 (−3.6–0.9) | >0.1 | — | — | — | — |
| Liraglutide | −0.60 (−2.3–1.1) | >0.1 | — | — | — | — |
| Obesity class | ||||||
| Overweight | ref | — | ref | — | ref | — |
| Class I (mild) | 3.51 (0.8–6.2) | 0.01 | 0.35 (0.1–0.6) | 0.003 | — | — |
| Class II (moderate) | 6.57 (4.0–9.1) | <0.001 | 0.33 (0.1–0.6) | 0.003 | −0.06 (−0.3–0.2) | >0.1 |
| Class III (severe) | 6.26 (3.9–8.6) | <0.001 | 0.31 (0.1–0.5) | 0.005 | 0.06 (−0.1–0.2) | >0.1 |
| Age at med initiation, years | −0.10 (−0.4–0.2) | >0.1 | 0.01 (0.0–0.0) | >0.1 | −0.03 (−0.1–0.0) | >0.1 |
| Female sex | −0.60 (−2.2–1.0) | >0.1 | −0.01 (−0.1–0.1) | >0.1 | 0.03 (−0.1–0.2) | >0.1 |
| Race | ||||||
| White | ref | — | ref | — | ref | — |
| Black | −1.87 (−3.9–0.2) | 0.07 | 0.04 (−0.1–0.1) | >0.1 | −0.27 (−0.5–0.0) | 0.05 |
| Hispanic | 0.25 (−1.6–2.1) | >0.1 | 0.00 (−0.1–0.1) | >0.1 | −0.16 (−0.4–0.1) | >0.1 |
| Asian | 0.23 (−4.0–4.5) | >0.1 | 0.03 (−0.1–0.1) | >0.1 | — | — |
| Insurance | ||||||
| Private | ref | — | ref | — | ref | — |
| Medicaid | 0.54 (−0.8–1.9) | >0.1 | −0.01 (−0.1–0.0) | >0.1 | 0.07 (−0.1–0.2) | >0.1 |
| Self-pay | −0.68 (−6.3–5.0) | >0.1 | 0.16 (−0.1–0.4) | >0.1 | — | — |
| Obesity-related illnesses, N | ||||||
| 0 | ref | — | ref | — | ref | — |
| 1–2 | 1.31 (−2.9–5.6) | >0.1 | −0.04 (−0.2–0.1) | >0.1 | −0.40 (−0.7–0.1) | 0.01 |
| 3–4 | 2.77 (−1.5–7.0) | >0.1 | 0.01 (−0.1–0.1) | >0.1 | −0.46 (−0.7–0.2) | <0.001 |
| 5–6 | 1.54 (−2.7–5.8) | >0.1 | −0.07 (−0.2–0.1) | >0.1 | −0.78 (−1.1–0.5) | <0.001 |
| ≥6 | 2.02 (−3.0–7.0) | >0.1 | −0.04 (−0.2–0.1) | >0.1 | −0.40 (−0.7–0.1) | 0.03 |
*
Coefficient indicates difference between respective medication and the overall frequency-weighted mean.
‡
N, patients with both pre-medication and post-medication weights recorded in chart. ref, reference group. Bold and italic value represents means-statistically significant.